• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Generic Perampanel Oral Suspension Proves Bioequivalent to Reference Formulation in Trial

by
November 13, 2026
in Health
Reading Time: 6 mins read
0
Generic Perampanel Oral Suspension Proves Bioequivalent to Reference Formulation in Trial

Generic Perampanel Oral Suspension Proves Bioequivalent to Reference Formulation in Trial

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A randomized, open-label crossover clinical trial evaluating two distinct formulations of perampanel oral suspension at a concentration of 0.5 milligrams per milliliter demonstrated that the generic drug Lepsiramp is bioequivalent to the branded reference formulation Fycompa when administered under fasting conditions to healthy adult human volunteers. Conducted at the Advanced Research Center in Cairo, Egypt, the clinical investigation evaluated the primary pharmacokinetic metrics required for bioequivalence certification, confirming that the geometric mean ratios for both peak drug exposure and cumulative systemic exposure fell entirely within standard international regulatory boundaries. Specifically, the test formulation exhibited a geometric mean ratio of 109.55 percent for peak plasma concentration, with a ninety percent confidence interval spanning 99.49 percent to 120.64 percent, alongside a ratio of 98.15 percent for the area under the plasma concentration-time curve up to seventy-two hours, with a ninety percent confidence interval ranging from 90.68 percent to 106.23 percent. Both intervals adhered to the eighty to one hundred twenty-five percent bioequivalence criteria.

The investigation addressed pharmacological treatment options for epilepsy, a chronic non-communicable neurological brain disease affecting approximately fifty million individuals across the globe, with a disproportionate burden borne by populations living in low-to-middle income countries who endure associated psychological, physical, and social complications. Regulatory authorities in the United States approved perampanel in 2012 as a once-daily oral treatment, authorized as both monotherapy and adjunctive therapy for managing focal-onset seizures, with or without secondarily generalized seizures, in pediatric and adult patients aged four years and older, while also approving it as an adjunctive treatment for primary generalized tonic-clonic seizures in patients twelve years of age and older.

From a clinical pharmacology standpoint, perampanel exhibits predictable dose linearity across a therapeutic dose range spanning 0.2 to 36 milligrams and undergoes rapid gastrointestinal absorption following oral administration without undergoing marked first-pass hepatic metabolism. When administered in tablet form alongside high-fat meals, the drug exhibits delayed absorption, shifting the time required to reach peak plasma concentration by approximately one hour in healthy subjects and between 0.5 and 2 hours in patients diagnosed with epilepsy, without altering overall systemic exposure or peak concentration. Perampanel binds extensively to circulating plasma proteins at a rate of approximately ninety-five percent and displays a prolonged terminal elimination half-life averaging 105 hours in human subjects. Hepatic clearance proceeds extensively through primary oxidation followed by sequential glucuronidation, biochemical pathways mediated primarily by cytochrome P450 3A enzymes, resulting in roughly seventy percent of the administered compound being eliminated in feces and thirty percent excreted in urine as a complex mixture of oxidative and conjugated metabolites.

Although solid oral tablets represent the conventional mode of perampanel administration, an oral suspension formulation delivering 0.5 milligrams per milliliter gained regulatory approval in 2016 for managing partial-onset seizures and primary generalized tonic-clonic seizures in patients aged twelve and older, with subsequent approval extended to children aged four and older using identical adult dosing recommendations. Liquid oral suspensions are clinically advantageous for individuals who experience swallowing difficulties or dysphagia, a complication frequently encountered among pediatric and geriatric patient demographics where epilepsy prevalence is statistically elevated compared to young adult populations. Because an affordable generic perampanel oral suspension had remained unavailable within the Egyptian pharmaceutical marketplace, researchers initiated this formal bioequivalence trial to evaluate Lepsiramp against the innovator reference product Fycompa to support local regulatory authorization by the Egyptian Drug Authority. Establishing bioequivalence ensures that alternative commercial drug preparations containing identical active pharmaceutical ingredients provide interchangeable clinical bioavailability, exhibiting no statistically meaningful divergence in absorption rate or absorption extent under identical testing parameters.

The clinical phase of the bioequivalence evaluation took place between January and April 2024 following formal protocol approval granted on February 17, 2024, by the Independent Ethics Committee of the Advanced Research Center under official protocol identification code IEC_170224_01, followed by retrospective registration on ClinicalTrials.gov under identifier NCT06969963 on May 13, 2025. All experimental procedures adhered to the ethical principles outlined in the 1964 Declaration of Helsinki and subsequent amendments, alongside the International Council for Harmonisation Guidelines for Good Clinical Practice. The study utilized a single-center, open-label, randomized, single-dose, two-period, two-sequence crossover framework conducted under strictly monitored fasting conditions. Prior to initiating any experimental interventions, investigators obtained and verified written informed consent from every participant, providing comprehensive clinical counseling regarding trial protocols, potential risks, and procedural expectations, while ensuring that all biological specimens and personal medical data were restricted strictly to the explicit analytical scope of the approved bioequivalence investigation.

The enrolled clinical cohort comprised twenty-six healthy adult volunteers, consisting of nineteen men and seven non-pregnant, non-lactating women who fulfilled all pre-specified eligibility requirements and successfully completed both intervention periods. The study population presented a mean age of 31.04 plus or minus 8.97 years, a mean height of 167.19 plus or minus 9.14 centimeters, a mean total body weight of 73.73 plus or minus 9.81 kilograms, and a mean body mass index of 26.37 plus or minus 2.67 kilograms per square meter, within the protocol-mandated range of 18.5 to less than 30 kilograms per square meter. Prospective volunteers underwent rigorous pre-randomization screening between day minus thirty and day minus three, involving comprehensive physical examinations, vital signs, anthropometric profiling, resting twelve-lead electrocardiograms, and diagnostic laboratory testing. Exclusion criteria barred individuals presenting organ dysfunction, chronic systemic illness, severe drug allergies, heavy tobacco smoking, alcohol or substance misuse, or recent systemic medication consumption within two weeks or six drug half-lives.

During each active treatment period, participants observed an overnight fast lasting at least ten hours and abstained from all fluid intake during the hour immediately preceding administration. Volunteers received a single oral dose consisting of twenty-four milliliters of oral suspension containing twelve milligrams of perampanel, administered alongside 240 milliliters of ambient water, using either the test product Lepsiramp, manufactured by Global Napi Pharmaceuticals for Global Advanced Pharmaceuticals in Cairo, or the German reference product Fycompa, manufactured by Eisai GmbH. Fluid restrictions were maintained until one hour post-dose, after which participants consumed standardized meals scheduled four and eight hours after administration to preserve uniform gastrointestinal conditions across cohorts. Crucially, the protocol separated the two treatment sequences by an extended six-week washout interval, equivalent to roughly ten elimination half-lives based on the 105-hour terminal half-life of perampanel, substantially exceeding the regulatory minimum of five half-lives to guarantee complete drug clearance and eliminate residual pharmacokinetic carryover.

Pharmacokinetic sample collection involved drawing twenty-two serial venous blood specimens of five milliliters each per volunteer throughout each seventy-two-hour study period, utilizing an intravenous cannula during the initial twenty-four hours followed by direct venipuncture at twenty-four, forty-eight, and seventy-two hours. Centrifugation occurred immediately at 3500 revolutions per minute for five minutes at four degrees Celsius, after which harvested plasma aliquots were frozen at minus eighty degrees Celsius pending quantification. Bioanalytical quantification employed liquid chromatography coupled with tandem mass spectrometry using an Acquity ultra-performance liquid chromatography platform connected to a Xevo triple quadrupole mass spectrometer. Separation occurred on a C18 column maintained at forty-five degrees Celsius with a mobile phase of aqueous ammonium formate, formic acid, and acetonitrile at 0.3 milliliters per minute. Ion transitions monitored were mass-to-charge ratios 350 to 219 for perampanel and 355 to 220 for deuterated perampanel-d5 internal standard, exhibiting validated linearity from three to 400 nanograms per milliliter.

Non-compartmental pharmacokinetic modeling executed via Phoenix WinNonlin derived primary absorption parameters, revealing a mean maximum plasma concentration of 379.67 plus or minus 113.59 nanograms per milliliter for Lepsiramp compared to 345.44 plus or minus 95.74 nanograms per milliliter for Fycompa. The area under the plasma concentration-time curve truncated at seventy-two hours yielded mean values of 10310.01 plus or minus 3012.19 nanogram-hours per milliliter for the test formulation and 10417.85 plus or minus 2602.39 nanogram-hours per milliliter for the reference formulation, while median time to reach peak concentration was 1.78 hours and 2.30 hours, respectively. Analysis of variance on log-transformed values revealed no statistically significant formulation effect for maximum concentration or cumulative area, confirming two one-sided tests within regulatory boundaries, alongside intra-subject variability of 19.35 percent for peak exposure and 12.73 percent for total exposure. While a sequence effect reached statistical significance, Wilcoxon testing confirmed no significant divergence in median absorption time between formulations.

Safety surveillance throughout the investigation revealed that both perampanel oral suspensions were well tolerated, with no serious adverse events, study withdrawals, or clinically abnormal alterations in blood pressure, pulse, respiratory rate, or body temperature observed. During the initial period, adverse events emerged in six participants, comprising dizziness in 15.38 percent of volunteers, headache in 3.84 percent, and nausea in 3.84 percent, whereas period two elicited adverse events in three individuals, presenting as headache, nausea, and hallucinations at 3.84 percent each. Subsequent hematological monitoring during follow-up identified mild laboratory fluctuations, including reduced hemoglobin in six volunteers, decreased red blood cell counts in two, and low white blood cell counts in one, with a single subject experiencing a moderate hemoglobin drop requiring targeted medication. Overall, the confirmation of bioequivalence establishes Lepsiramp as a therapeutically interchangeable, affordable generic alternative to Fycompa oral suspension, broadening practical therapeutic accessibility for patients requiring non-tablet antiepileptic regimens.

Subject of Research: Bioequivalence evaluation of generic and reference perampanel oral suspension formulations

Article Title: Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study

Article References: AbdelMagid, A. M., Badr, K. A., & Rezk, M. R. (2025). Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study. Drugs in R&D, 25(4), 343-351. https://doi.org/10.1007/s40268-025-00526-5

Image Credits: AI Generated

DOI: 10.1007/s40268-025-00526-5

Keywords: perampanel, bioequivalence, oral suspension, epilepsy, pharmacokinetics, clinical pharmacology, generic drugs, crossover study, Oral, Suspension, Formulations, Healthy

News Source: Ophelia Keating. (November 13, 2026). Generic Perampanel Oral Suspension Proves Bioequivalent to Reference Formulation in Trial. Scienmag.

Tags: bioequivalenceclinical pharmacologycrossover studyepilepsyformulationsgeneric drugsHealthyOraloral suspensionperampanelPharmacokineticssuspension
Share12Tweet7Share2ShareShareShare1

Related Posts

Rotavirus Vaccine Reduces Hospitalization for Laboratory-Confirmed Gastroenteritis in Southern Italy

Rotavirus Vaccine Reduces Hospitalization for Laboratory-Confirmed Gastroenteritis in Southern Italy

November 18, 2026
Clobazam Review Highlights Pharmacological Nuance and Polytherapy Dosing in Difficult Epilepsies

Clobazam Review Highlights Pharmacological Nuance and Polytherapy Dosing in Difficult Epilepsies

November 18, 2026

Fibroblast-Derived MDK Signaling Drives Lymph Node Metastasis in Luminal Breast Cancer

November 18, 2026

Continuous Innate Immunity Score Predicts Sepsis Mortality and Stratifies Treatment Response

November 18, 2026

POPULAR NEWS

  • Epilepsy Marks Lower Adaptive Functioning in Boys With MECP2 Duplication Syndrome

    Epilepsy Marks Lower Adaptive Functioning in Boys With MECP2 Duplication Syndrome

    29 shares
    Share 12 Tweet 7
  • Geno2pheno Overestimates CXCR4 Tropism in Chinese HIV-1 CRF01_AE Clinical Isolates

    29 shares
    Share 12 Tweet 7
  • Climate Variability Drives Growing Global Risks Across Foodborne Pathogen Pathways

    29 shares
    Share 12 Tweet 7
  • Catheter Drainage Reduces Surgical Burden While Endoscopy Accelerates Early Hemorrhage Clearance

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Physics-Embedded Artificial Intelligence Framework Enhances Flight Stability for Flapping-Wing Aerial Robots

Rotavirus Vaccine Reduces Hospitalization for Laboratory-Confirmed Gastroenteritis in Southern Italy

Clobazam Review Highlights Pharmacological Nuance and Polytherapy Dosing in Difficult Epilepsies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.